Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8852W HIGH $9.48
Volume
29.57 K
Value Traded
80.71 K
Short % Float
1.15%
Days to Cover
1.1
-7.34%Week
-14.41%1 Month
-36.08%3 Month
-68.92%6 Month
-98.93%5 Year
-99.38%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
6.61 M
EPS (TTM)
-1.27
P/E Ratio
-
Ent. Value
4.89 M
Total Shares
6.55 M
Float Shares
3.73 M
Insiders
42.98%
Institutions
2.09%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
XCUR Catalyst Timeline
Dated clinical, regulatory and corporate events for Exicure, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Exicure, Inc.
275Total events
7Upcoming
61Tier-1 (high impact)
2016 to 2026Coverage
Upcoming catalysts 2
Event history 50
▼Equity OfferingCorporate
Issuance of 172,058 shares to GPCR Therapeutics in settlement of milestone payment
●Milestone PaymentGPC-100Corporate
Clinical milestone payment triggered by Phase 2 completion to be settled via equity issuance
▼Restructuring LayoffsCorporate
Implementation of cost-reduction and restructuring initiatives including termination of non-essential legacy consulting arrangements
▼Quarterly UpdateCorporate
Received Nasdaq notice for non-compliance with minimum stockholders' equity requirement
▼Timing GuidancePresentation
Nasdaq notified Exicure of non-compliance with Listing Rule 5550(b)(1) minimum stockholders' equity
▲Partnership / LicenseGPC-100Corporate
Co-development agreement with Adbiotech for Burixafor (GPC-100)
sickle cell disease, acute myeloid leukemia, solid tumorssource ↗
▼Going ConcernCorporate
Going concern disclosure: cash may not sustain operations for next 12 months
◆Poster PresentationGPC-100Presentation
Poster presentation of Phase 2 trial data at 2026 Tandem Meetings
multiple myelomasource ↗
▲PublicationGPC-100Presentation
Publication of Phase 2 study results in Annals of Hematology
multiple myeloma, non-Hodgkin's lymphoma, Hodgkin diseasesource ↗
▲Oral PresentationGPC-100Presentation
Presentation at Tandem Meetings February 2026
multiple myelomasource ↗
▲Topline ReadoutGPC-100Clinical Data
Positive topline data from Phase 2 trial
multiple myelomasource ↗
●Milestone PaymentGPC-100Corporate
Clinical milestone payment of $1.0 million triggered by Phase 2 completion
▲Oral PresentationGPC-100Presentation
Oral presentation of Phase 2 data for burixafor in multiple myeloma at 2025 ASH Annual Meeting
multiple myelomasource ↗
▲Topline ReadoutGPC-100Clinical Data
Positive topline Phase 2 data for burixafor in multiple myeloma
multiple myelomasource ↗
▲Trial CompletionGPC-100Trial
Phase 2 trial of burixafor in multiple myeloma completed
multiple myelomasource ↗
▲Topline ReadoutGPC-100Clinical Data
Positive topline data from Phase 2 study with propranolol presented at ASH 2025 and Tandem Meetings 2026
multiple myelomasource ↗
▲Management ChangeCorporate
Appointment of Devki Sukhtankar as Head of Preclinical Research and Translational Medicine
◆Topline ReadoutGPC-100Clinical Data
Announce clinical trial results in September
blood cancer (HSCT for multiple myeloma)source ↗
▲Last Patient Last VisitGPC-100Trial
Final patient completed last study visit in Phase 2 trial
multiple myelomasource ↗
◆Enrollment CompleteGPC-100Trial
Complete administration of GPC-100 to 20 patients by April
blood cancer (HSCT for multiple myeloma)source ↗
◆Quarterly UpdateCorporate
Company expects to provide additional update on strategic discussions in January
◆Enrollment UpdateGPC-100Trial
Two additional patients to receive GPC-100 treatment in January
blood cancer (HSCT for multiple myeloma)source ↗
◆Management ChangeCorporate
Board expanded to nine directors; four new directors and two officers appointed
▲Oral PresentationGPC-100Presentation
Presented results at ASH conference in December 2024
blood cancer (AML)source ↗
▼Equity OfferingCorporate
Agreement to sell 2,900,000 additional shares to HiTron for $8.7 million
▼Restructuring LayoffsCorporate
Restructuring and suspension of clinical and development activities
▼Equity OfferingCorporate
Exchanged approximately $1,000,000 of indebtedness for equity at $3.00 per share
●Going ConcernCorporate
Received extension from Nasdaq Hearings Panel to evidence compliance by November 14, 2024
Past FDA Catalysts and PDUFA Decisions
How XCUR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-02-05 | Burixafor (GPC-100) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 76%
Micro Cap(rank 500 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GPC-100 Small moleculeCompletedNCT05561751 | Multiple Myeloma | Phase 2 | COMPLETED | 30 | Oct 31, 2025 | ||||||
| AST-008 Small moleculeCompletedNCT03086278 | Undisclosed | Phase 1 | COMPLETED | 16 | Aug 16, 2018 |
Clinical Trial Results
Readouts, endpoints and source filings for every XCUR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| burixafor | multiple myeloma and lymphoma | Phase 2 | 2026-02-05 | 92%, 11 of 12 participants, 12 days, 22 days, 11-foldRead More | Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing TransplantRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Exicure HiTron Inc.10% Owner | Other | 117,441 2,222,224 held | $4.50 | 07/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in XCUR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PROSIGHT MANAGEMENT, LP | 0.3 % (-91.2 %) | 490.00 K | 2.43 M | -52.65% ( -2.70 M) |
XCUR Institutional Ownership Trends
XCUR Short Interest
Shares sold short, counted twice a month.
1.15%
Short % of Float
of tradable shares sold short
42.9K
Shares Sold Short
+14.2% vs prior count
1.1 Low
Days to Cover
trading days of normal volume to buy every short share back
40.7K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How XCUR ranks across every disease it competes in
Competitive Position is a premium feature
See how XCUR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialXCUR News
XCURExicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement
Exicure, Inc. has been granted an extension by Nasdaq until December 2, 2026, to meet the stockholders' equity requirement after previously failing to comply. The company is working on compliance initiatives but faces risks of potential delisting if it does not meet the requirements. Nasdaq will continue to monitor Exicure's progress during this period.
Read more →XCURExicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
Exicure, Inc. plans to issue 172,058 shares to GPCR Therapeutics to settle a $1 million clinical milestone payment following the completion of the Phase 2 trial of Burixafor. The shares will be issued at a deemed value of $5.81 each, with the transaction expected to finalize in August 2026. This approach helps Exicure preserve cash while pursuing its strategic priorities.
Read more →XCUR▼ -5.5%on this news
Exicure Announces Board and Committee Changes
Exicure, Inc. has announced changes to its Board of Directors, including the resignation of Jung Kyu Ham and the appointment of Jin Young Go and Eui Seok Han as new directors. The Board size has increased from five to six members, maintaining compliance with Nasdaq independence standards. Additionally, a new Compensation Committee has been established.
Read more →XCURExicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
Exicure, Inc. received a notification from Nasdaq indicating non-compliance with the minimum stockholders' equity requirement. The company reported equity of approximately $2.1 million, below the $2.5 million threshold. Exicure plans to submit a compliance plan within 45 days and is exploring options to improve its financial standing. The notification does not immediately affect its stock listing.
Read more →XCUR▼ -6.6%on this news
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
Exicure, Inc. received a delinquency notice from Nasdaq due to a delay in filing its Quarterly Report on Form 10-Q for Q1 2026. The delay was attributed to changes in financial reporting personnel. However, the company has since filed the report and believes it has regained compliance with Nasdaq regulations. Exicure is also exploring strategic alternatives following a restructuring.
Read more →XCURExicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
Exicure, Inc. has entered a co-development agreement with Adbiotech to explore combination therapies using Burixafor (GPC-100) in several therapeutic areas, including sickle cell disease and acute myeloid leukemia. The collaboration will see Adbiotech conduct preclinical research while Exicure will lead clinical strategies. Notably, Burixafor has shown promise after completing a Phase 2 trial in multiple myeloma, laying a foundation for further studies. The agreement aims to advance clinical programs and secure funding for future development.
Read more →XCURSummary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
Exicure, Inc. announced a proposed settlement regarding a stockholder derivative action, which alleges breaches of fiduciary duty by individual defendants. The settlement includes corporate governance reforms aimed at preventing future issues. A hearing is scheduled for June 2, 2026, to determine the fairness of the settlement and related fees. Current stockholders will not receive individual compensation.
Read more →XCURExicure, Inc. Reports Full Year 2025 Financial Results
Exicure, Inc. reported its financial results for 2025, revealing a net loss of $4.9 million, an improvement from $9.7 million in 2024. The company faces liquidity challenges, with cash reserves insufficient for the next year. Increased expenses stem from the acquisition of GPCR Therapeutics, highlighting the need for additional financing to sustain operations.
Read more →XCURUNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION IN RE EXICURE, INC. DERIVATIVE LITIGATION This Document Relates to ALL ACTIONS Lead Case No. 1 22-cv-01083 EXHIBIT C NOTICE OF PENDENCY AND PROP
Exicure, Inc. is poised to settle a derivative litigation case involving allegations of fiduciary breaches by former directors. The settlement, proposed on March 18, 2026, includes the implementation of new corporate governance reforms aimed at benefiting the company and its stockholders. However, if approved, current stockholders will be barred from contesting the settlement and pursuing related claims in the future. The court is set to hold a hearing on June 2, 2026, to evaluate the fairness and adequacy of the proposed settlement.
Read more →XCURExicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant
Exicure, Inc. announced the publication of a Phase 2 study in the Annals of Hematology, highlighting the efficacy of burixafor in rapidly mobilizing stem cells in patients with multiple myeloma and lymphoma undergoing transplant. The study showed that 92% of participants achieved the primary endpoint, with significant increases in white blood cell subsets. Burixafor's rapid mobilization profile may simplify treatment logistics and reduce patient burden.
Read more →XCURExicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings
Exicure, Inc. will present data from its Phase 2 trial of burixafor at the 2026 Tandem Meetings. The trial evaluated burixafor's effectiveness in mobilizing hematopoietic progenitor cells for patients with multiple myeloma undergoing autologous transplantation. The study reported a high success rate in achieving the primary endpoint, highlighting burixafor's potential as a reliable mobilization strategy.
Read more →XCUR▲ +36.8%on this news
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting
Exicure, Inc. announced positive results from its Phase 2 trial of burixafor for multiple myeloma. Approximately 90% of participants achieved the primary endpoint for hematopoietic progenitor cell mobilization. The combination therapy was well tolerated, showing a rapid mobilization of cells and an excellent safety profile. These findings were presented at the 67th ASH Annual Meeting.
Read more →XCURExicure, Inc. Reports Third Quarter 2025 Financial Results
Exicure, Inc. reported its financial results for Q3 2025, showing a net loss of $2.4 million, up from $1.1 million in Q3 2024. The company’s cash position has declined to $4.4 million, raising concerns about its ability to fund operations. Increased expenses were attributed to the acquisition of GPCR Therapeutics USA Inc., and management indicated a need for substantial additional financing.
Read more →XCURNew Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting
Exicure, Inc. announced that results from its Phase 2 study of burixafor will be presented at the 67th ASH Annual Meeting. The study demonstrated an excellent safety profile and effective mobilization of hematopoietic progenitor cells in multiple myeloma patients. The oral presentation will take place on December 8, 2025, highlighting promising data.
Read more →XCURExicure Highlights Recent Achievements and Near-term Strategic Priorities
Exicure, Inc. has reported significant progress on its lead program, burixafor (GPC-100), which is nearing a key Phase 2 trial readout for multiple myeloma. Interim results indicate 100% success in stem cell mobilization. The company is also preparing to expand burixafor's application to other diseases and has strengthened its leadership team with experienced professionals in drug development.
Read more →XCURExicure, Inc. Reports Second Quarter 2025 Financial Results
Exicure, Inc. reported its second quarter 2025 financial results, revealing a net loss of $2.6 million, a significant increase compared to the previous year's loss of $0.6 million. This loss was primarily attributed to higher operating expenses following the recent acquisition of GPCR Therapeutics. The company's cash reserves have declined to $7.9 million, raising concerns about its financial stability and ability to continue its operations without additional funding. Management indicated the need for substantial financing in the short term to sustain the business.
Read more →XCUR▲ +10.4%on this news
Exicure, Inc. (Nasdaq XCUR) Regains Compliance with Nasdaq Filing Requirements
Exicure, Inc. announced that it has regained compliance with Nasdaq's filing requirements as of July 1, 2025. A notice from Nasdaq confirmed the resolution of the compliance matter following the filing of its periodic reports for the fiscal quarter ended March 31, 2025. The company, which focuses on developing nucleic acid therapies, is currently exploring strategic alternatives to maximize value for its shareholders. This compliance marks a positive turn for the company amidst its restructuring efforts.
Read more →XCURExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
Exicure, Inc. has received a notice of non-compliance from Nasdaq due to the late filing of its Form 10-Q for the quarter ending March 31, 2025. The Company has 60 days to submit a plan to regain compliance, with the possibility of an extension up to 180 days if accepted by Nasdaq. Exicure is diligently working to complete the necessary filings and maintain its listing on the exchange.
Read more →XCURExicure, Inc. Reports Full Year 2024 Financial Results CHICAGO, IL
Exicure, Inc. has reported its full-year 2024 financial results, revealing a significant cash position increase to $12.5 million. However, the company suspended all research and development activities and is exploring strategic alternatives due to concerns about funding operations. Their net loss decreased to $(9.7) million, yet there remains a substantial doubt about the company's viability without additional financing. Legal expenses related to litigation have also increased, indicating ongoing challenges.
Read more →XCUR▼ -15.1%on this news
Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics, Inc. CHICAGO, IL.
Exicure, Inc. has entered a Share Purchase Agreement with GPCR Therapeutics, Inc., acquiring GPCR USA to enhance its technology portfolio. In tandem with this acquisition, they established a License and Collaboration Agreement to develop GPCR's therapeutics and address milestone payments related to clinical trials and royalties. GPCR USA is advancing a Phase 2 clinical trial focused on blood cancer treatments. However, Exicure is currently navigating potential Nasdaq listing compliance issues which could impact its operations going forward.
Read more →About Exicure, Inc.
Headquarters2430 N. HALSTED ST., CHICAGO, IL, 60614
BIOPHARMAWATCH ELITE PLUS
Trade the next XCUR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime